Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GENGRAF vs PROTOPIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcineurin inhibitor; binds to cyclophilin, inhibits calcineurin-dependent T-cell activation, preventing nuclear factor of activated T-cells (NF-AT) dephosphorylation and translocation, thereby reducing IL-2 and other cytokine gene transcription.
Tacrolimus, a calcineurin inhibitor, binds to FKBP-12 and inhibits calcineurin, thereby blocking dephosphorylation and nuclear translocation of NFAT, reducing transcription of pro-inflammatory cytokines (e.g., IL-2, IFN-γ) in T-cells.
Prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants,Treatment of active rheumatoid arthritis (FDA-approved for moderate to severe),Treatment of psoriasis (FDA-approved for severe, recalcitrant cases),Off-label: nephrotic syndrome, aplastic anemia, ulcerative colitis, atopic dermatitis
Moderate to severe atopic dermatitis in non-immunocompromised patients where conventional therapy is inadvisable or ineffective,Prophylaxis of organ rejection in kidney or liver transplantation (systemic use, not topical),Off-label: Treatment of vitiligo, psoriasis, eczema of the face and neck (short-term)
5-15 mg/kg/day orally in divided doses every 12 hours.
Apply a thin layer of 0.03% or 0.1% ointment to affected areas twice daily. Discontinue when lesions resolve. For adults, use 0.03% or 0.1%; 0.1% is not indicated for children.
Terminal half-life is approximately 8.4 hours (range 5-18 hours) in adult volunteers; prolonged in hepatic impairment.
Terminal half-life ranges from 6–20 hours in pediatric atopic dermatitis patients; prolonged in hepatic impairment (mean 8–35 hours).
Hepatic metabolism primarily via CYP3A4 enzyme; also substrate for CYP3A5. Metabolized to multiple metabolites with variable activity, including AM1 (hydroxylated), AM9 (N-demethylated), and AM4N (cyclized). Undergoes extensive first-pass metabolism.
Primarily hepatic via CYP3A4; also metabolized by CYP3A5. Topical absorption results in minimal systemic exposure, but systemic metabolism follows oral route.
Primarily biliary/fecal (94%); renal excretion accounts for 6% (0.1% unchanged).
Primarily fecal (biliary) elimination of metabolites; <1% of parent drug excreted unchanged in urine.
90-98% bound to plasma proteins, primarily lipoproteins, albumin, and alpha-1-acid glycoprotein.
99% bound primarily to albumin and alpha-1-acid glycoprotein.
3.5 L/kg (range 1.2-4.8 L/kg) in renal transplant recipients; distribution is extensive and variable.
Vd/F ~ 30–50 L/kg after oral administration, indicating extensive tissue distribution; topical absorption negligible.
Oral bioavailability is 30% (range 10-60%), variable due to first-pass metabolism and food effects.
Systemic bioavailability after topical application is <0.5% in adults with intact skin; increases in compromised skin barrier.
GFR <30 m L/min: reduce dose by 50%.
No dose adjustment required. Tacrolimus is not significantly renally excreted and systemic absorption is minimal.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use.
No specific dose adjustment for Child-Pugh class A or B. For severe hepatic impairment (Child-Pugh C), use with caution; consider starting at lower concentration (0.03%) due to potential increased systemic exposure.
4-10 mg/kg/day orally in divided doses every 12 hours; adjusted to target trough levels.
Children (2-15 years): Apply 0.03% ointment twice daily. Do not use 0.1% in this age group. For children 2 years and older.
Initiate at lower end of dosing range and titrate based on renal function and drug levels.
No specific dose adjustment required. Use minimum effective amount; monitor for cutaneous infections.
Increased susceptibility to infection and development of lymphoma and other malignancies, particularly of the skin. Only physicians experienced in immunosuppressive therapy and management of transplant patients should prescribe cyclosporine.
Long-term safety of topical calcineurin inhibitors has not been established. Although a causal relationship has not been established, rare cases of malignancy (e.g., lymphoma, skin cancer) have been reported in patients treated with topical calcineurin inhibitors. Therefore, continuous long-term use should be avoided, and application should be limited to areas of involvement.
Nephrotoxicity: Monitor renal function regularly; risk increased with high doses, other nephrotoxic drugs, or prolonged use.,Hepatotoxicity: Monitor liver function.,Hypertension: Common; require blood pressure control.,Neurotoxicity: Including tremor, convulsions, headache, and paresthesias.,Hyperkalemia: Monitor serum potassium, especially with potassium-sparing diuretics or ACE inhibitors.,Hypomagnesemia: Supplementation may be required.,Increased risk of infections and lymphoproliferative disorders.,Potential for anaphylactic reactions with IV formulation (due to Cremophor EL).,Carcinogenesis: Especially skin malignancies; minimize UV exposure.
Increased risk of infections (including herpes simplex, eczema herpeticum); avoid use on malignant or premalignant skin conditions; use with caution in patients with netherton syndrome; may cause photosensitivity; avoid concurrent UV exposure; monitor for lymphadenopathy; not for use in children <2 years (safety not established).
Hypersensitivity to cyclosporine or any component of the formulation (including Cremophor EL for IV),Uncontrolled hypertension,Malignancy (except non-melanoma skin cancer) in patients with rheumatoid arthritis or psoriasis,Concomitant use with PUVA or UVB therapy, methotrexate, other immunosuppressive agents, or coal tar (for psoriasis patients),Abnormal renal function with uncontrolled hypertension (for psoriasis patients),Pregnancy (category C; additional risk of premature birth and low birth weight)
Hypersensitivity to tacrolimus or any component of the formulation; use in patients with known or suspected malignancy at the application site; use in immunocompromised patients (relative).
Grapefruit and grapefruit juice increase cyclosporine levels and must be avoided. High-potassium foods (e.g., bananas, oranges, potatoes) may increase hyperkalemia risk; monitor intake. Avoid St. John's wort as it reduces drug levels.
No known food interactions with topical PROTOPIC. However, if absorbed systemically (rare), grapefruit juice may increase tacrolimus levels; avoid excessive consumption of grapefruit juice while using PROTOPIC.
First trimester: Cyclosporine crosses the placenta. Limited human data, but no major malformations attributed. Second and third trimesters: Risk of intrauterine growth restriction, prematurity, and low birth weight. Consider risk-benefit; avoid if possible, but may be used if essential.
Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at systemic exposures below human therapeutic levels. No adequate human studies in pregnant women. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: avoid if possible. Second and third trimesters: limited data; systemic absorption minimal with topical use, but theoretical risk remains.
Cyclosporine is excreted into breast milk. Milk-to-plasma ratio approximately 0.3-0.6. Potential for infant immunosuppression and growth inhibition. Weigh benefits against risks; monitor infant for adverse effects.
Not known if tacrolimus is excreted in human milk after topical administration. Systemic absorption is minimal (<0.5%), but caution is advised due to potential for infant immunosuppression. M/P ratio: not available. Consider benefit of breast-feeding vs risk of infant exposure.
Pregnancy reduces cyclosporine oral bioavailability and increases clearance; dose may need to be increased by 20-50% to maintain therapeutic trough levels. Frequent level monitoring recommended, especially in third trimester. Postpartum dose reduction likely needed.
No specific dose adjustments recommended for topical use due to minimal systemic absorption. However, limit application to smallest area and shortest duration needed. Avoid use on large areas, broken skin, or under occlusion to reduce systemic exposure.
Monitor trough levels (target 100-400 ng/m L) and renal function closely. Calcineurin inhibitors cause nephrotoxicity; dose reduction may be necessary. Avoid use with potassium-sparing diuretics or ACE inhibitors due to hyperkalemia risk. Grapefruit increases levels; avoid coadministration. Remember to adjust dose for hepatic impairment.
PROTOPIC (tacrolimus) is a topical calcineurin inhibitor used for atopic dermatitis. It is steroid-sparing, thus avoiding skin atrophy and tachyphylaxis. Apply as a thin layer to affected areas. Avoid occlusive dressings. Can be used on face, neck, and intertriginous areas where topical steroids are riskier. Monitor for burning/stinging upon application, which often improves with continued use. Warn patients about rare risk of lymphoma and skin malignancy; use only as second-line therapy for short-term and intermittent treatment. Do not use in immunocompromised patients or those with active skin infections.
Take with or without food consistently at the same times each day.,Do not consume grapefruit or grapefruit juice while on this medication.,Report signs of infection, tremors, or changes in urine output immediately.,Avoid live vaccinations and limit sun exposure due to increased skin cancer risk.,Do not stop or change dose without consulting your doctor.
Apply PROTOPIC exactly as prescribed; do not use more than directed.,Wash hands after application unless treating hands.,Do not cover treated area with bandages or dressings unless instructed.,Expect mild burning or stinging especially in the first few days; this usually resolves with continued use.,Avoid sun exposure and use sunscreen; protect treated areas from natural and artificial sunlight.,Do not use on infected skin; tell your doctor if you have an infection.,PROTOPIC is for external use only; do not get in eyes, mouth, or nose.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Store at room temperature away from moisture and heat.,Report any signs of skin infection, rash, or swollen lymph nodes to your doctor immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GENGRAF vs PROTOPIC, answered by our medical review team.
GENGRAF is a Calcineurin Inhibitor Immunosuppressant that works by Calcineurin inhibitor; binds to cyclophilin, inhibits calcineurin-dependent T-cell activation, preventing nuclear factor of activated T-cells (NF-AT) dephosphorylation and translocation, thereby reducing IL-2 and other cytokine gene transcription.. PROTOPIC is a Topical Calcineurin Inhibitor that works by Tacrolimus, a calcineurin inhibitor, binds to FKBP-12 and inhibits calcineurin, thereby blocking dephosphorylation and nuclear translocation of NFAT, reducing transcription of pro-inflammatory cytokines (e.g., IL-2, IFN-γ) in T-cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GENGRAF and PROTOPIC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GENGRAF is: 5-15 mg/kg/day orally in divided doses every 12 hours.. The standard adult dose of PROTOPIC is: Apply a thin layer of 0.03% or 0.1% ointment to affected areas twice daily. Discontinue when lesions resolve. For adults, use 0.03% or 0.1%; 0.1% is not indicated for children.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GENGRAF and PROTOPIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GENGRAF is classified as Category C. First trimester: Cyclosporine crosses the placenta. Limited human data, but no major malformations attributed. Second and third trimesters: Risk of intrauterine growth restriction,. PROTOPIC is classified as Category C. Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at systemic exposures below human therapeutic levels. No adequate human studies in pregnant women.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.